Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients

Armakolas,Athanasios; Stathopoulos,George  P.; Nezos,Adrianos; Theos,Apostolos; Stathaki,Martha; Koutsilieris,Michael

doi:10.3892/or.2012.2018

Subdivision of molecularly-classified groups by new gene signatures in breast cancer patients

Authors:
- Athanasios Armakolas
- George P. Stathopoulos
- Adrianos Nezos
- Apostolos Theos
- Martha Stathaki
- Michael Koutsilieris
View Affiliations

Affiliations: Laboratory of Experimental Physiology, Medical School, National and Kapodestrian University of Athens, Athens 11527, Greece, First Oncology Clinic, Errikos Dunant Hospital, Athens 11526, Greece
Published online on: September 5, 2012 https://doi.org/10.3892/or.2012.2018
Pages: 2255-2263

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gene expression patterns as well as gene interactions are under investigation for their involvement in tumour heterogeneity. The molecular classification of breast cancer based on hormone receptor expression, grade and HER2 receptor levels, is indicative but not adequate enough to complete the prognostic data. The objectives of this study were to validate the prognostic value of 19 genes, solely, and as parts of classifiers (sets of genes), in breast cancer patients and to determine whether the expression of these genes and classifiers is correlated with breast cancer molecular classification. Gene expression was examined in the blood of 88 breast cancer patients and 50 healthy controls using multiplex quantitative real-time PCR. Patients with a second primary malignancy showed a statistically significant difference when compared with: i) patients with a single breast cancer, for an 8-gene classifier (p<0.02); and ii) healthy individuals (classifier FBX033, FLJ339115) (p<0.01), with respect to gene expression. The classifier ENY2, USP38 was associated with the development of primary breast cancer. A newly established classifier (ENY2, USP38, RPS7, Osbpl-1 and ETF1) indicated a statistically significant association with HER2 subtype patients, compared to patients with a different molecular classification (p<0.04). The gene FLJ33915 was differentially expressed in a subgroup of HER2-positive patients with infiltrated axillary lymph nodes (p<0.028). We validated the prognostic value of 4 classifiers for primary and second primary malignancy. Evidence of a classifier predicting the HER2 subtype and the gene FLJ33915 which subdivides HER2 subtype patients is also presented.

View Figures

View References

1	Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med. 360:790–800. 2009. View Article : Google Scholar : PubMed/NCBI
2	Oakman C, Santarpia L and Di Leo A: Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol. 7:723–732. 2010. View Article : Google Scholar : PubMed/NCBI
3	Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, et al: Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 10:R652008. View Article : Google Scholar : PubMed/NCBI
4	Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG, Glas AM, Perou CM and Van’t Veer LJ: Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res. 65:9155–9158. 2005. View Article : Google Scholar : PubMed/NCBI
5	Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 27:1160–1167. 2009. View Article : Google Scholar : PubMed/NCBI
6	Correa Geyer F and Reis-Filho JS: Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? Int J Surg Pathol. 17:285–302. 2009.PubMed/NCBI
7	Cosler LE and Lyman GH: Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Invest. 27:953–959. 2009. View Article : Google Scholar : PubMed/NCBI
8	Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast tumours. Nature. 406:747–752. 2000. View Article : Google Scholar : PubMed/NCBI
9	Feng Y, Li X, Sun B, Wang Y, Zhang L, Pan X, Chen X, Wang X, Wang J and Hao X: Evidence for a transcriptional signature of breast cancer. Breast Cancer Res Treat. 122:65–75. 2009. View Article : Google Scholar
10	Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez- Angulo AM, Lluch A, Gray JW, Brown PH and Hilsenbeck S: Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER⁺ breast cancer. Breast Cancer Res. 12:R402010. View Article : Google Scholar
11	Chernov AV, Baranovskaya S, Golubkov VS, Wakeman DR, Snyder EY, Williams R and Strongin AY: Microarray-based transcriptional and epigenetic profiling of matrix metalloproteinases, collagens, and related genes in cancer. J Biol Chem. 285:19647–19659. 2010. View Article : Google Scholar
12	Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI
13	Miecznikowski JC, Wang D, Liu S, Sucheston L and Gold D: Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways. BMC Cancer. 10:5732010. View Article : Google Scholar
14	Chen H, Pimienta G, Gu Y, Sun X, Hu J, Kim MS, Chaerkady R, Gucek M, Cole RN, Sukumar S and Pandey A: Proteomic characterization of Her2/neu-overexpressing breast cancer cells. Proteomics. 16:3600–3610. 2010.
15	Tebbit CL, Zhai J, Untch BR, Ellis MJ, Dressman HK, Bentley RC, Baker JA, Marcom PK, Nevins JR, Marks JR and Olson JA Jr: Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat. 118:635–643. 2009. View Article : Google Scholar
16	Centeno BA, Enkemann SA, Coppola D, Huntsman S, Bloom G and Yeatman TJ: Classification of human tumors using gene expression profiles obtained after microarray analysis of fine-needle aspiration biopsy samples. Cancer. 105:101–109. 2005. View Article : Google Scholar
17	Stathopoulos GP and Armakolas A: Differences in gene expression between individuals with multiple primary and single primary malignancies. Int J Mol Med. 24:613–622. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sørlie T: Molecular classification of breast tumors: toward improved diagnostics and treatments. Methods Mol Biol. 360:91–114. 2007.PubMed/NCBI
19	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: hnRNP C is required for postimplantation mouse development but Is dispensable for cell viability. Mol Cell Biol. 20:4094–4105. 2000.PubMed/NCBI
20	Adachi Y, Pavlakis GN and Copeland TD: Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia. J Biol Chem. 269:2258–2262. 1994.
21	Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N and Bachs O: The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem. 278:1158–1164. 2003. View Article : Google Scholar : PubMed/NCBI
22	Ozbek U, Kandilci A, van Baal S, et al: SET-CAN the product of t(9;9) in acute undifferentiated leukaemia, causes expansion of early haematopoietic progenitors and hyperproliferation of stomach mucosa in transgenic mice. Am J Pathol. 171:654–666. 2007. View Article : Google Scholar
23	Ralph S, Brenchley PE, Summers A, Rosa DD, Swindell R and Jayson GC: Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma. Cancer Sci. 98:844–849. 2007. View Article : Google Scholar : PubMed/NCBI
24	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
25	Lutz M, Wempe F, Bahr I, Zopf D and von Melchner H: Proteasomal degradation of the multifunctional regulator YB-1 is mediated by an F-Box protein induced during programmed cell death. FEBS Lett. 580:3921–3930. 2006. View Article : Google Scholar : PubMed/NCBI
26	Antonicka H, Ostergaard E, Sasarman F, Weraarpachai W, Wibrand F, Pedersen AM, Rodenburg RJ, van der Knaap MS, Smeitink JA, Chrzanowska-Lightowlers ZM and Shoubridge EA: Mutations in C12orf65 in patients with encephalomyopathy and a mitochondrial translation defect. Am J Hum Genet. 87:115–122. 2010. View Article : Google Scholar : PubMed/NCBI
27	Sowa ME, Bennett EJ, Gygi SP and Harper JW: Defining the human deubiquitinating enzyme interaction landscape. Cell. 138:389–403. 2009. View Article : Google Scholar : PubMed/NCBI
28	Torrini M, Marchese C, Vanzetti M, Marini V, Origone P, Garré C and Mareni C: Mutation analysis of oxisterol-binding-protein gene in patients with age-related macular degeneration. Genet Test. 11:421–426. 2007. View Article : Google Scholar : PubMed/NCBI
29	Chen D, Zhang Z, Li M, Wang W, Li Y, Rayburn ER, Hill DL, Wang H and Zhang R: Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene. 26:5029–5037. 2007. View Article : Google Scholar : PubMed/NCBI
30	Costanzo M, Baryshnikova A, Bellay J, Kim Y, Spear ED, Sevier CS, Ding H, Koh JL, Toufighi K, Mostafavi S, et al: The genetic landscape of a cell. Science. 22: 327:425–431. 2010.
31	Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM and Kohn EC: CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation: accumulation of poly-ubiquitinated Hsp90 client proteins. J Biol Chem. 278:28490–28500. 2003. View Article : Google Scholar
32	Du X, Nagata S, Ise T, Stetler-Stevenson M and Pastan I: FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood. 111:338–343. 2008. View Article : Google Scholar : PubMed/NCBI
33	Malek SN, Dordai DI, Reim J, et al: Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase. Proc Natl Acad Sci USA. 95:7351–7356. 1998. View Article : Google Scholar : PubMed/NCBI
34	Tschumper RC, Geyer SM, Campbell ME, et al: Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. J Clinc Invest. 118:306–315. 2008. View Article : Google Scholar : PubMed/NCBI
35	Vitek L and Schwertner HA: The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem. 43:1–57. 2007. View Article : Google Scholar : PubMed/NCBI
36	Mani A and Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol. 23:4776–4789. 2005. View Article : Google Scholar : PubMed/NCBI
37	Yanagisawa M, Huveldt D, Kreinest P, et al: p120 catenin isoform switch affects Rho activity, induces tumor cell invasion and predicts metastatic disease. J Biol Chem. 283:18344–18354. 2008. View Article : Google Scholar